A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

BACKGROUND: Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients with advanced, refractory solid tumours. METHODS: Sunitinib was initially admi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Boven, E, Massard, C, Armand, J P, Tillier, C, Hartog, V, Brega, N M, Countouriotis, A M, Ruiz-Garcia, A, Soria, J C
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2010
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2965864/
https://ncbi.nlm.nih.gov/pubmed/20717111
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605852
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados